Objective To compare the effect of minimally invasive hematoma the quenching aspiration and hematoma evacuation in the treatment of hypertensive basal ganglia brain hemorrhage.Methods 92 patients with hypertensive cerebral basal ganglia hemorrhage underwent surgical treatment were randomly divided into two groups:minimally invasive quenching suction group of 46 patients,craniotomy group of 46 patients.The mortality,complications and activities of daily living(ADL) postoperative three months were observed.Results The mortality rate of the minimally invasive quenching suck group was lower than that of the craniotomy group (8.7％ vs 21.7％,P ＜ 0.05).The postoperative rebleeding and the incidence rate of complications such as lung infections in the minimally invasive quenching suction group were lower than those of the craniotomy group(all P ＜ 0.05).ADL score 3 months postoperatively of the minimally invasive quenching suction group was higher than that of the craniotomy group [(85.53 ± 13.47) points vs (56.12 ± 11.72) points,P ＜ 0.05].Conclusion Minimally invasive hematoma the quenched aspiration in treatment of hypertensive basal ganglia brain bleeding trauma can reduce the mortality,reduce the occurrence of postoperative complications,increase quality of life in patients,has better efficacy for treatment of hypertensive intracerebral hemorrhage.

OBJECTIVE:To prepare epirubicin hydrochloride solid lipid nanoparticle(EPI-SLN) and investigate its physicochemical property. METHODS: EPI-SLN was prepared by ultrasonic dispersion technique with glyceryl behenate as matrix,and the appearance,particle size,? electric potential,and entrapment efficiency of the SLN were evaluated and its stability at 3 month storing at 4 ℃ was investigated. RESULTS: EPI-SLN assumed spherical shape with a particle diameter of (212.8?6.2) nm,? electric potential of (-24.7?0.3) mV and entrapment efficiency of 82 %. The EPI-SLN at 4 ℃ was stable after storing for 3 months,showing no marked change in mean diameter,? electric potential or entrapment efficiency. CONCLUSION: The prepared EPI-SLN is up to the standard.

Objective:To analyze the risk factors of hospital-acquired pneumonia (HAP) after craniocerebral trauma.Methods:A total of 329 patients undergoing craniocerebral trauma surgery from December 2014 to December 2019 in Yicheng People′s Hospital of Zaozhuang City were enrolled. The data were reviewed and divided into HAP group (42 patients) and non-HAP group (287 patients) according to whether HAP occurred after surgery. The age, onset to operation time, surgery duration, and hospital stay between the two groups were compared. The differences of preoperative factors, intraoperative factors and postoperative factors between the two groups were compared. The risk factors of HAP after craniocerebral trauma were analyzed by Logistic multi-factor regression analysis.Results:The age, onset to operation time, surgery duration, hospital stay in HAP group were longer than those in the non-HAP group: (55.09 ± 8.14) years vs. (45.98 ± 8.06) years, (9.65 ± 0.54) h vs. (7.43 ± 0.72) h, (332.54 ± 72.65 )min vs. (281.09 ± 78.54) min, (17.13 ± 2.56) d vs. (5.02 ± 3.09), the differences were statistically significant ( P<0.05). The differences in the types of brain diseases between the two groups were statistically significant ( P<0.05). The results of single factor analysis showed that the history of pulmonary disease, scores of Glasgow Coma Scale (GCS) < 8 points and ≥8 points, whether or not emergency operation, preoperatie antibiotics, reintubated, endotracheal intubation, indwelling gastric tube, and raise the head of a bed 30° to 45°, proton pump inhibitors, craniocerebral trauma and non traumatic diseases, mechanical ventilation, floor nutrition start time, giving glucocorticoid between the HAP group and non-HAP group had significant difference ( P<0.05). The Logistic multi-factor regression analysis showed that the age >50 years old, surgery duration >4 h, preoperative GCS<8 points, emergency surgery, tracheotomy and indwelling gastric tube were independent risk factors of HAP after surgery ( P<0.05). Conclusions:For patients undergoing surgical treatment of craniocerebral trauma, it is necessary to estimate the risk of postoperative HAP based on age, preoperative GCS score, elective surgery after emergency, operation time, and control risk factors.

Objective: To explore the inhibitory effect of icotinib combined with cytokine induced killer (CIK) on various human lung adenocarcinoma cell lines in vitro. Methods: The inhibitory effect of icotinib alone or icotinib combined with CIK on HCC827 and A549 cells was detected by cell counting kit-8(CCK-8). The apoptosis was detected by flow cytometry via Annexin V/PI staining. The effect of icotinib on CIK phenotype was detected by flow cytometry. Results: The inhibitory rates of HCC827 cells treated with 1.5, 3, 6, 12 μmol/L icotinib were (5.64±0.05)%, (8.62±0.45)%, (14.57±0.65)% and (18.52±0.91)%, respectively. The inhibitory rates of A549 cells were (1.64±0.48)%, (2.09±0.28)%, (3.69±0.45)%, (4.41±0.58)%, respectively. At the same concentration, the inhibitory rate of HCC827 cells with icotinib treatment was significantly higher than that of A549 cells (P<0.05). When the effector/target ratio was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells co-cultured with CIK were (15.17±2.33)%, (42.59±7.18)%, (62.59±8.95)%, respectively, and the inhibitory rates of A549 were(16.99±2.81)%, (46.31±1.89)%, (58.24±4.23)%, respectively. The inhibitory rate of HCC827 cells co-cultured with CIK was not significantly different from that of A549 cells at the same effector/target ratio (P_10∶1=0.299, P_20∶1=0.318, P_40∶1=0.366). When the effector/target ratio of CIK combined with 6 μmol/L icotinib was 10∶1, 20∶1 or 40∶1, the inhibitory rates of HCC827 cells were (37.07±3.50)%, (76.03±6.55)%, (80.34±10.69)%, respectively, and the inhibitory rates of A549 cells were(25.72±1.41)%, (52.76±3.82)%, (62.26±1.94)%, respectively. The inhibitory rates of 6 μmol/L icotinib combined with CIK were significantly higher than those of icotinib group and CIK group alone at the same effector/target ratio (P<0.05), except for the effector/target ratio at 40︰1 on A549 cells (P=0.089). Moreover, all of the combination index (CI) of combined group were <1 (P<0.05). The apoptotic rates of HCC827 and A549 cells induced by icotinib combined with CIK were significantly higher than those of icotinib group and blank control group (P<0.05), especially the proportion of late apoptotic or necrotic cells.Increasing effector/target ratio of CIK contributed to stronger inhibition(P<0.05). The expressional rate of CIK phenotype with or without icotinib treatment was not significantly different from each other(P>0.05). Conclusions EGFR mutant lung adenocarcinoma cells are more sensitive to icotinib, while the EGFR mutation status has no effect on the killing effect of CIK cells. icotinib combined with CIK has a synergistic effect on the inhibition of tumor growth, and icotinib has no any impact on the phenotype of CIK cells.